Topics

Novartis AG: Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies

01:33 EDT 30 Aug 2019 | FinanzNachrichten

In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary en...

Original Article: Novartis AG: Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies

NEXT ARTICLE

More From BioPortfolio on "Novartis AG: Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies"

Quick Search

Relevant Topic

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...